CYP17A1
Steroid 17-alpha-hydroxylase/17,20 lyase
As of the edition of 20 October 2026, CYP17A1 (steroid 17-alpha-hydroxylase/17,20 lyase, UniProt P05093) has 8 drugs tested at it and 13 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05093
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 17
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue; Hormones; Pregnancy and women's health; Infections; Immune system; Digestive system
- Registered trials of its drugs
- 479
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Abiraterone acetate | Marketed | Phase 4 | Ends 2038 |
| Ketoconazole | Marketed | Phase 4 | none listed |
| Abiraterone | Marketed | Phase 4 | none listed |
| Orteronel | Stopped | Phase 3 | none listed |
| Levoketoconazole | Marketed | Phase 3 | Ends 2028 |
| Seviteronel | Stopped | Phase 2 | none listed |
| Galeterone | Went quiet | Phase 3 | none listed |
| JNJ-212082 | Went quiet | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 4 |
| Undetermined | 5 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| SCRI Development Innovations | Route A |
| Cortendo | Route B |
| Ltn Pharmaceuticals | Route A |
The other 10 companies at CYP17A1
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at CYP17A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.